Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JHM03
- Development stage
- Phase 3
- Lead developer
- JHM Biopharmaceutical
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
JHM03 is a recombinant botulinum toxin type A developed as an injectable biologic for the treatment of moderate to severe glabellar lines and upper limb spasticity. It is positioned as a next-generation botulinum toxin product, offering advantages such as higher purity, increased batch yields, streamlined processing, and reduced immunogenic impurities compared to traditional botulinum toxins. The drug acts primarily as a neuromuscular blocking agent by inhibiting acetylcholine release at the neuromuscular junction, leading to temporary muscle paralysis. Additional mechanisms may include acetylcholinesterase inhibition and glutamate antagonism. Developed by JHM BioPharma (Tonghua), it is currently in phase I/II clinical trials for cosmetic and neurological indications[1][4][5][6].
- Brand names
- Eveotox
- Other names
- recombinant botulinum toxin type A (JHM03)
02
Targets
SNAP25 (Synaptosome-associated protein 25)Muscle-type nicotinic acetylcholine receptorAcetylcholinesteraseGluR (Glutamate receptors)
Beyond the preview
Go deeper on JHM03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JHM03.